Salute e Benessere

Ipsen initiates a share buy-back program to cover its free employee…

Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share planPARIS, FRANCE, 3 June 2024 -Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 400,000, or about 0.47% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen's free employee share-allocation...
Nasdaq GlobeNewswire
03/06/2024

New data with daridorexant to be presented at SLEEP 2024

Allschwil, Switzerland – June 3, 2024Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults with insomnia, will be presented at SLEEP 2024 – the 38 thAnnual Meeting of the Associated Professional Sleep Societies, taking place in Houston, Texas, from June 1– 5, 2024.Posters for daridorexant include the following: Kaufmann P, et al. Excretion of the dual orexin receptor antagonist daridorexant into...
Nasdaq GlobeNewswire
03/06/2024

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

As part of the BLA submission process, Telix has requested a Priority Review under the eligibility criteria of the Breakthrough Therapy designation[6]. If granted, this would potentially support an expedited review time. If Zircaix®[2] is approved, TLX250-CDx will be the first targeted radiopharmaceutical imaging agent specifically for kidney cancer to be commercially available in the U.S. and further builds on Telix's successful urology imaging franchise. As part of the BLA submission…
PR Newswire
03/06/2024

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody®…

Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide (R 2 ) experienced a 95% overall response rate (ORR) Results from the optimization cohort of the EPCORE™ NHL- 1 study show that mitigation strategies led to a clinically significant reduction in rate of cytokine release...
Nasdaq GlobeNewswire
02/06/2024

Allergic diseases directly cost between 1,800 and 6,600 euros per patient per…

The HEAD registry, with nearly 800 patients, serves to evaluate the economic and social impact of allergies at a European level VALENCIA, Spain, June02, 2024(GLOBE NEWSWIRE) -- Allergic diseases cost between 1,823€ and 6,656€ per patient per year if we only consider the direct costs derived from healthcare, according to a study of the data collected through the European HEAD registry promoted by the EAACI, which is holding its congress at the Feria de Valencia until Monday, June 3...
Nasdaq GlobeNewswire
02/06/2024

KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering

JEDDAH, Saudi Arabia, June02, 2024(GLOBE NEWSWIRE) -- In an era where healthcare innovation is paramount, KFSHRC Jeddah has made headway in the treatment of severe Xanthoma through the deployment of a modified plasma exchange protocol. This milestone underscores KFSHRC's position as a trailblazer in healthcare innovation and patient care, particularly in addressing complex cases.Xanthoma, characterized by the accumulation of triglyceride-filled deposits beneath the skin, signals not...
Nasdaq GlobeNewswire
02/06/2024

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in…

Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment48% ORR in evaluable anti-PD-1 naïve patients (n=25); 28% ORR in evaluable anti-PD-1 resistant patients (n=25) as per RECIST 1.176% DCR in evaluable naïve patients; 68% DCR in evaluable resistant patients as per RECIST 1.1Preliminary review of survival data in ITT...
Nasdaq GlobeNewswire
02/06/2024

CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly®…

CHMP recommendation is primarily based on the results of GEMSTONE-302, a multi-center, randomized, double-blind, Phase 3 clinical trial. Sugemalimab in combination with chemotherapy significantly improved PFS and OS compared to placebo in combination with chemotherapy in previously untreated stage IV NSCLC patients. The study results have been published in The Lancet Oncology and Nature Cancer and reported in oral sessions at various international academic conferences. CHMP recommendation is...
PR Newswire
01/06/2024

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with…

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024 COPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024—...
Nasdaq GlobeNewswire
01/06/2024

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with…

Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive mNSCLC treated with combination of acasunlimab with pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024Genmab...
Nasdaq GlobeNewswire
01/06/2024

Ultimovacs Announces Poster Presentation at the 2024 American Society of…

NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website: https://meetings.asco...
Nasdaq GlobeNewswire
01/06/2024

RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC ("Bidco") which is…

MANHATTAN BEACH, Calif., June 01, 2024 /PRNewswire/ -- On 24 May 2024, Bidco and K1 announced that the offer document (the "Offer Document") in relation to Bidco's offer to acquire the entire issued and to be issued share capital of MariaDB plc (the "Offer") had been published and posted to shareholders of MariaDB plc. MANHATTAN BEACH, Calif.,June 01, 2024/PRNewswire/ -- On 24 May 2024, Bidco and K1 announced that the offer document (the " Offer Document ") in…
PR Newswire
01/06/2024

EAACI Congress Kicks Off in Valencia, Spain

Precision Medicine, Immunotherapy, and Artificial Intelligence (AI) as Key Topics VALENCIA, Spain, May31, 2024(GLOBE NEWSWIRE) -- The EAACI International Congress has commenced with the slogan “Revolutionizing patient care through the power of data science.” Over the next four days, experts will discuss the latest advancements in this impactful area. Allergies, which represent a significant public health issue, encompass a variety of conditions. Drug allergy is a major adverse...
Nasdaq GlobeNewswire
31/05/2024

Groupe Casino: Disposal of 90 stores to Groupement Les Mousquetaires and Auchan…

Disposal of 90 stores to GroupementLes Mousquetaires and Auchan Retail France Paris, 31 May 2024Following the agreements reached on 24 January 2024, with Groupement Les Mousquetaires and Auchan Retail France and as well as on 8 February 2024, with Carrefour to sell a combined total of 287 stores, Casino Group announces today the sale of 90 stores 1. The disposals of the remaining 76 stores will occur on 1 July 2024. This transaction is based on an enterprise value of the stores...
Nasdaq GlobeNewswire
31/05/2024

Valneva Receives EMA's Positive CHMP Opinion for its Chikungunya Vaccine

If approved, IXCHIQ ®will become the first vaccine available in the EU against the chikungunya virus (CHIKV)Decision on EU marketing authorization expected in the third quarter of 2024 Saint Herblain (France), May 31, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization...
Nasdaq GlobeNewswire
31/05/2024

Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of…

COPENHAGEN, Denmark, May 31, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a freeze-dried formulation of JYNNEOS ®for prevention of smallpox and mpox disease in adults 18 years of age and older.The liquid-frozen formulation of JYNNEOS ®was approved by the FDA in September 2019. It remains the only approved mpox vaccine anywhere in the world...
Nasdaq GlobeNewswire
31/05/2024

AB Science is providing a summary of the live webcast held on May 30, 2024…

PRESS RELEASESUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISParis, May 31, 2024, 4.30pm CETAB Science SA(Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)...
Nasdaq GlobeNewswire
31/05/2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per...
Nasdaq GlobeNewswire
31/05/2024

Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

The ConfIdeS trial is evaluating kidney function in 64 highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care. A total of 24 US sites are participating in the trial and its primary endpoint is kidney graft function at 12 months, measured by eGFR (estimated Glomerular Filtration Rate). The ConfIdeS trial is evaluating kidney function in 64 highly sensitized (cPRA ≥99.9%)…
PR Newswire
31/05/2024

Kinomica Announces Multiple Abstracts on its KScan® Precision Oncology…

"We are delighted to be able to showcase multiple elements of the KScan® platform and illustrate how these components coalesce into a biomarker discovery capability that provides insights that would otherwise be unobtainable," said Arran Dokal PhD, CTO of Kinomica. "It's well accepted that quantitative phosphoproteomics provides unique biological information that is not captured by other technologies, but any clinical utilization of the technology has been considered challenging…
PR Newswire
31/05/2024

As the second European Myasthenia Gravis Awareness Day unfolds, 'All United for…

BRUSSELS, May 31, 2024 /PRNewswire/ -- There is a notable gap in the understanding and recognition of the severity of MG In Europe, resulting in disparities in patient care. Many patients are left underserved, highlighting the need for heightened awareness about this rare autoimmune neuromuscular disease and its implications for patients and their caregivers. BRUSSELS,May 31, 2024/PRNewswire/ -- There is a notable gap in the understanding and recognition of the severity of MG In Europe,...
PR Newswire
31/05/2024

Novartis Scemblix® Phase III data first to show superior efficacy with a…

Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix ®(asciminib) demonstrated superior MMR rates at week 48 vs. investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib) (67.7% vs. 49.0%) and imatinib alone (69.3% vs. 40.2%) 1 Scemblix also demonstrated a favorable safety and tolerability profile vs. imatinib and 2G TKIs, with fewer grade ≥3 AEs, dose adjustments, and half the...
Nasdaq GlobeNewswire
31/05/2024

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024.Sanofi's global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10 thyear, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to secure that employees benefit from the company growth and success.Paul Hudson Chief Executive Officer of Sanofi “This plan underscores our ongoing commitment to unite the...
Nasdaq GlobeNewswire
31/05/2024

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Investor Relations Tobias Bjorklund+45 3077 8682 tobb@novonesis.com Anders Enevoldsen+45 5350 1453 adev@novonesis.com ...
Nasdaq GlobeNewswire
31/05/2024
Altri  Comunicati